Drug
Mgl 3196
Mgl 3196: highest development phase Phase 3, developed by Madrigal Pharmaceuticals. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Madrigal Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| MGL-3196 NCT03900429 | Phase 3 | NASH - Nonalcoholic Steatohepatitis |
| MGL-3196 (resmetirom) NCT03038022 | Phase 2 | Heterozygous Familial Hypercholesterolemia |
| MGL-3196 NCT02912260 | Phase 2 | Non-alcoholic Steatohepatitis |
| MGL-3196 NCT03220165 | Phase 1 | Healthy |
| MGL-3196 NCT04643795 | Phase 1 | Hepatic Impairment |
| MGL-3196 Tablet NCT03413124 | Phase 1 | Healthy |
| MGL-3196 NCT04671069 | Phase 1 | Healthy |
| MGL-3196 NCT04671056 | Phase 1 | Healthy |
Latest
No recent events.
Follow Mgl 3196 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.